Asta아스타

Asta's revenue is shrinking and its losses are deep, with the share price down 28% over the past year.

Asta sells MALDI-TOF mass spectrometry instruments and consumables for microbial identification in hospitals and labs, plus industrial instruments for display, battery and semiconductor quality control. Trailing twelve-month revenue to H1 2026 was about ₩3.5B against an operating loss of about ₩2.9B, and the company holds about ₩9.3B in cash against about ₩0.5B in borrowings. The data shows a market value of about ₩99B at ₩6,070 per share.

What stands out

• Trailing revenue of about ₩3.5B is down from ₩3.4B in 2024 and ₩2.6B in 2025 shows a 22.7% drop, with operating margin around -85% on the trailing figures.
• Net losses have been large in each year from 2021 to 2025, and free cash flow over the trailing period was about -₩4.0B.
• The company's own discounted cash flow model gives a base value of ₩13 per share, far below the current price, and a bear value of ₩122; the bull value is listed as 0, so the range is not meaningful for decision-making.
• The filings include a half-year report with an adverse audit opinion flag on capital impairment and an equity under ₩1B confirmation, plus a lawsuit filed or ruled and a change of largest shareholder.
• A major sales or supply contract was filed on 6 October 2026, but the data does not give its value or terms.

What to watch

• The details and outcome of the lawsuit filed or ruled on 21 October 2026, which the data does not describe.
• Whether the largest shareholder change and several 5%+ holding reports signal further ownership shifts; the data does not say why.
• Whether the adverse audit opinion and capital impairment issues are resolved in the next filings, and whether revenue stabilises given the continued operating losses.